{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:57:57Z","timestamp":1791917877807,"version":"4.3.4"},"reference-count":30,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Angelini"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Data on antibiotic treatment for diabetic foot osteomyelitis are limited. This study aims to describe the real-world effectiveness and safety of dalbavancin in treating deep diabetic foot infections. Methods: A retrospective, observational, multicenter study was conducted in nine Spanish hospitals and one Irish hospital. Patients with diabetic foot osteomyelitis treated with dalbavancin were included. Data on demographics, clinical characteristics, microbiology, antibiotic regimens, adverse events, and clinical outcomes were analyzed. Results: Among 136 patients, 76% were male, with a mean age of 69 \u00b1 12 years. Renal insufficiency was observed in 32%, and 6% required renal replacement therapy. Based on the McCabe scale, 70% of patients had a rapidly or ultimately fatal disease. Polypharmacy was noted in 83%, and 60% of infections were moderate. Dalbavancin was primarily used as second-line therapy (92%). The cure rate was 80.9% (95% CI: 73.5\u201386.6%), achieved after a median of two doses. Patients receiving dalbavancin as first-line therapy had a cure rate of 86%, comparable to 80% in second-line therapy, with no significant differences. Surgical interventions were required in 72% of cases, with minor amputations performed in 40% of patients. Polymicrobial infections were common (55%), and methicillin-resistant Staphylococcus aureus was identified in 26% of cases. Adverse events occurred in 5% of patients. Chronic kidney disease was the sole independent risk factor for therapeutic failure (IRR 0.80, 95% CI: 0.64\u20131.00, p = 0.045). Conclusions: Dalbavancin is effective and safe for treating diabetic foot osteomyelitis, including in complex patients with resistant microorganisms.<\/jats:p>","DOI":"10.3390\/jcm14196705","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T13:48:37Z","timestamp":1758635317000},"page":"6705","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-World Use of Dalbavancin in Diabetic Foot Osteomyelitis: PEDDAL Study"],"prefix":"10.3390","volume":"14","author":[{"given":"Leonor Moreno","family":"N\u00fa\u00f1ez","sequence":"first","affiliation":[{"name":"Infectious Diseases Department, Hospital Universitario Fundaci\u00f3n Alcorc\u00f3n, Universidad Rey Juan Carlos, 28922 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Rueda","family":"Benito","sequence":"additional","affiliation":[{"name":"Microbiology Department, Sligo University Hospital, F91H684 Sligo, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8603-779X","authenticated-orcid":false,"given":"Elena","family":"Bereciartua","sequence":"additional","affiliation":[{"name":"Infectious Disease Department, Cruces University Hospital, Biobizkaia Research Institute, 48903 Baracaldo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5795-0814","authenticated-orcid":false,"given":"Laura","family":"Morata","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Clinic-IDIBAPS, Universitat de Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5736-8111","authenticated-orcid":false,"given":"Rosa","family":"Escudero-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Infectious Disease Department, Hospital Ram\u00f3n y Cajal (Madrid), IRYCIS (Instituto Ram\u00f3n y Cajal de Investigaci\u00f3n Sanitaria), CIBERINFEC (Centro de Investigaci\u00f3n Biom\u00e9dica en Red Enfermedades Infecciosas), 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0209-6494","authenticated-orcid":false,"given":"Julia Sellares","family":"Nadal","sequence":"additional","affiliation":[{"name":"Infectious Disease Department, Hospital Universitari Vall d\u2019Hebron, Vall d\u2019Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1752-1382","authenticated-orcid":false,"given":"Joan","family":"G\u00f3mez-Junyent","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital del Mar, Institut Hospital del Mar d\u2019Investigacions M\u00e8diques (IMIM), Universitat Pompeu Fabra, 08003 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro Salinas","family":"Botr\u00e1n","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Hospital Cl\u00ednico San Carlos, Universidad Complutense de Madrid, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6380-4717","authenticated-orcid":false,"given":"Ana Mar\u00eda Arn\u00e1iz","family":"Garc\u00eda","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Gerencia de Atenci\u00f3n Especializada, \u00c1reas III y IV: Hospital Sierrallana y Tres Mares, Servicio C\u00e1ntabro de Salud, 39300 Torrelavega, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4935-8754","authenticated-orcid":false,"given":"Mar\u00eda Dolores","family":"del Toro L\u00f3pez","sequence":"additional","affiliation":[{"name":"Unidad Cl\u00ednica de Enfermedades Infecciosas y Microbiolog\u00eda, Hospital Universitario Virgen Macarena, Universidad de Sevilla, Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 41009 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Ruiz-Cabrera","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Universitario Fundaci\u00f3n Alcorc\u00f3n, Universidad Rey Juan Carlos, 28922 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Miguel Ramos","family":"Andrino","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Universitario Fundaci\u00f3n Alcorc\u00f3n, Universidad Rey Juan Carlos, 28922 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma","family":"Alidrous","sequence":"additional","affiliation":[{"name":"Microbiology Department, Sligo University Hospital, F91H684 Sligo, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8215-3603","authenticated-orcid":false,"given":"Marina","family":"Tor\u00edo-Salvador","sequence":"additional","affiliation":[{"name":"Infectious Disease Department, Cruces University Hospital, Biobizkaia Research Institute, 48903 Baracaldo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7870-0515","authenticated-orcid":false,"given":"Miguel \u00c1ngel","family":"Verdejo","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Clinic-IDIBAPS, Universitat de Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6554-2095","authenticated-orcid":false,"given":"Mar\u00eda","family":"Velasco Arribas","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Universitario Fundaci\u00f3n Alcorc\u00f3n, Universidad Rey Juan Carlos, 28922 Madrid, Spain"},{"name":"Research Unit, Hospital Universitario Fundaci\u00f3n Alcorc\u00f3n, GEIO-SEIMC, 28922 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"key":"ref_1","unstructured":"IDF Diabetes Atlas (2025, April 04). Regional Factsheets. Available online: https:\/\/diabetesatlas.org\/."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Nieto-Gil, P., Ortega-Avila, A.B., Pardo-Rios, M., Cobo-Najar, M., Blasco-Garcia, C., and Gijon-Nogueron, G. (2018). Hospitalisation Cost of Patients with Diabetic Foot Ulcers in Valencia (Spain) in the Period 2009\u20132013: A Retrospective Descriptive Analysis. Int. J. Environ. Res. Public Health, 15.","DOI":"10.3390\/ijerph15091831"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.7326\/0003-4819-117-2-97","article-title":"Risk factors for amputation in patients with diabetes mellitus. A case-control study","volume":"117","author":"Reiber","year":"1992","journal-title":"Ann. Intern. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.1002\/dmrr.836","article-title":"Diabetic foot osteomyelitis: A progress report on diagnosis and a systematic review of treatment","volume":"24","author":"Berendt","year":"2008","journal-title":"Diabetes\/Metab. Res. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"\u00c1lvaro-Afonso, F.J., Garc\u00eda-\u00c1lvarez, Y., Tard\u00e1guila-Garc\u00eda, A., Garc\u00eda-Madrid, M., L\u00f3pez-Moral, M., and L\u00e1zaro-Mart\u00ednez, J.L. (2023). Bacterial Diversity and Antibiotic Resistance in Patients with Diabetic Foot Osteomyelitis. Antibiotics, 12.","DOI":"10.3390\/antibiotics12020212"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.2165\/11538070-000000000-00000","article-title":"Methicillin-Resistant Staphylococcus aureus in Diabetic Foot Infections","volume":"70","author":"Eleftheriadou","year":"2010","journal-title":"Drugs"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ijid.2018.02.013","article-title":"Influence of multidrug resistant organisms on the outcome of diabetic foot infection","volume":"70","author":"Saltoglu","year":"2018","journal-title":"Int. J. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Matta-Guti\u00e9rrez, G., Garc\u00eda-Morales, E., Garc\u00eda-\u00c1lvarez, Y., \u00c1lvaro-Afonso, F.J., Molines-Barroso, R.J., and L\u00e1zaro-Mart\u00ednez, J.L. (2021). The Influence of Multidrug-Resistant Bacteria on Clinical Outcomes of Diabetic Foot Ulcers: A Systematic Review. J. Clin. Med., 10.","DOI":"10.3390\/jcm10091948"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s13300-022-01357-2","article-title":"The Role of Novel Antibiotics in the Management of Diabetic Foot Infection","volume":"14","author":"Mougakou","year":"2023","journal-title":"Diabetes Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-weekly dalbavancin versus daily conventional therapy for skin infection","volume":"370","author":"Boucher","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.diagmicrobio.2018.10.007","article-title":"Dalbavancin for the management of gram-positive osteomyelitis: Effectiveness and potential utility","volume":"93","author":"Almangour","year":"2019","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"ofy331","DOI":"10.1093\/ofid\/ofy331","article-title":"Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety","volume":"6","author":"Rappo","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jgar.2023.11.015","article-title":"Dalbavancin real-life utilization among diabetic patients suffering from infections in Italy and Spain: The DALBADIA retrospective cohort study","volume":"36","author":"Ruiz","year":"2024","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_14","first-page":"296","article-title":"Experience in the use of dalbavancin in diabetic foot infection","volume":"40","year":"2022","journal-title":"Enferm. Infecc. Microbiol. Clin. Engl. Ed."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"243","DOI":"10.5455\/medarh.2020.74.243-245","article-title":"Successful Treatment of Diabetic Foot Osteomyelitis with Dalbavancin","volume":"74","author":"Loupa","year":"2020","journal-title":"Med. Arch."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e3687","DOI":"10.1002\/dmrr.3687","article-title":"IWGDF\/IDSA Guidelines on the Diagnosis and Treatment of Diabetes-related Foot Infections (IWGDF\/IDSA 2023)","volume":"40","author":"Senneville","year":"2024","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1093\/cid\/ciw445","article-title":"Diagnostic Accuracy of Probe to Bone to Detect Osteomyelitis in the Diabetic Foot: A Systematic Review","volume":"63","author":"Lam","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1464-5491.2010.03150.x","article-title":"Diagnosing diabetic foot osteomyelitis: Is the combination of probe-to-bone test and plain radiography sufficient for high-risk inpatients?","volume":"28","author":"Lipsky","year":"2011","journal-title":"Diabet. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","article-title":"Validation of a combined comorbidity index","volume":"47","author":"Charlson","year":"1994","journal-title":"J. Clin. Epidemiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/1757177415617245","article-title":"The reliability of the McCabe score as a marker of co-morbidity in healthcareassociated infection point prevalence studies","volume":"17","author":"Reilly","year":"2016","journal-title":"J. Infect. Prev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jclinepi.2012.02.018","article-title":"Polypharmacy cutoff and outcomes: Five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes","volume":"65","author":"Gnjidic","year":"2012","journal-title":"J. Clin. Epidemiol."},{"key":"ref_22","unstructured":"(2022, June 20). Adverse Event|European Medicines Agency (europa.eu). Available online: https:\/\/www.ema.europa.eu\/en\/glossary\/adverse-event."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e1539","DOI":"10.1093\/cid\/ciaa1758","article-title":"Three versus six weeks of antibiotic therapy for diabetic foot osteomyelitis: A prospective, randomized, non-inferiority pilot trial","volume":"73","author":"Gariani","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00203-020-01818-x","article-title":"Diabetes-associated infections: Development of antimicrobial resistance and possible treatment strategies","volume":"202","author":"Akash","year":"2020","journal-title":"Arch. Microbiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s15010-019-01354-x","article-title":"Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection","volume":"47","author":"Tobudic","year":"2019","journal-title":"Infection"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ijantimicag.2017.11.008","article-title":"Dalbavancin in the treatment of different gram-positive infections: A real-life experience","volume":"51","author":"Bouza","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"106918","DOI":"10.1016\/j.ijantimicag.2023.106918","article-title":"EN-DALBACEN 2.0 Cohort: Real-life study of dalbavancin as sequential\/consolidation therapy in patients with infective endocarditis due to Gram-positive cocci","volume":"62","author":"Loeches","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_28","first-page":"86","article-title":"Dalbavancin as sequential therapy in infective endocarditis: Real-life experience in elder and comorbid patients","volume":"43","author":"Heredia","year":"2024","journal-title":"Enferm. Infecc. Microbiol. Clin. Engl. Ed."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"106842","DOI":"10.1016\/j.ijantimicag.2023.106842","article-title":"Dalbavancin vs standard of care for Staphylococcus aureus bacteraemia in patients unable to receive outpatient parenteral antimicrobial therapy","volume":"62","author":"Frazier","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/AAC.04550-14","article-title":"Extended-Duration Dosing and Distribution of Dalbavancin into Bone and Articular Tissue","volume":"59","author":"Dunne","year":"2015","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/19\/6705\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:47:43Z","timestamp":1760035663000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/19\/6705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":30,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["jcm14196705"],"URL":"https:\/\/doi.org\/10.3390\/jcm14196705","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,23]]}}}